Patents by Inventor Derek LONDESBROUGH
Derek LONDESBROUGH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240010628Abstract: A method of manufacturing R-MDMA by forming a Grignard reagent from 5-bromobenzodioxole, treating the Grignard reagent with S-propylene oxide to form chirally pure alcohol 1, activating the alcohol as mesylate 2, converting to chirally pure azide 3, reducing the azide to amine 4, protecting the amine with di-tert-butyl dicarbonate, reducing the protected amine 5 to yield R-MDMA free base 6, and treating with an acid to form a salt 7 in >99% e.e. A method of manufacturing S-MDMA by forming a Grignard reagent from 5-bromobenzodioxole, treating the Grignard reagent with R-propylene oxide to form chirally pure alcohol 8, activating the alcohol as mesylate 9, converting to chirally pure azide 10, reducing the azide to amine 11, protecting the amine with di-tert-butyl dicarbonate, reducing the protected amine 12 to yield S-MDMA free base 13, and treating with an acid to form a salt 14 in >99% e.e.Type: ApplicationFiled: June 29, 2023Publication date: January 11, 2024Applicant: Mind Medicine, Inc.Inventors: Stephen E. SCHNEIDER, Derek LONDESBROUGH
-
Publication number: 20230250059Abstract: Syntheses of compounds of Formula III from compounds of Formula I via compounds of Formula II are described, as well as particular compounds of Formula III, or pharmaceutically acceptable salts thereof, compositions comprising such compounds, and uses thereof. For example, certain of these compounds and compositions of Formula III have uses in the treatment of psychiatric or neurological disorders.Type: ApplicationFiled: March 31, 2023Publication date: August 10, 2023Applicant: Small Pharma LtdInventors: Peter RANDS, George KNIGHT, Richard CHUBB, Derek LONDESBROUGH, Tiffanie BENWAY, Zelah JOEL
-
Publication number: 20230167056Abstract: The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, as well as compositions comprising such compounds. These compounds and compositions have uses in the treatment of psychiatric or neurological disorders. Compounds of formula I comprise at least one deuterium atom at the ?-position and consequently have improved oral bioavailability relative to ?-diprotic analogues.Type: ApplicationFiled: January 10, 2023Publication date: June 1, 2023Applicant: Small Pharma LtdInventors: Peter RANDS, George KNIGHT, Richard CHUBB, Derek LONDESBROUGH, Tiffanie BENWAY, Zelah JOEL
-
Patent number: 11643390Abstract: Syntheses of compounds of Formula III from compounds of Formula I via compounds of Formula II are described, as well as particular compounds of Formula III, or pharmaceutically acceptable salts thereof, compositions comprising such compounds, and uses thereof. For example, certain of these compounds and compositions of Formula III have uses in the treatment of psychiatric or neurological disorders.Type: GrantFiled: August 26, 2021Date of Patent: May 9, 2023Assignee: Small Pharma LtdInventors: Peter Rands, George Knight, Richard Chubb, Derek Londesbrough, Tiffanie Benway, Zelah Joel
-
Publication number: 20230104823Abstract: The present invention relates to a process for preparing a compound of formula [I], or a pharmaceutically acceptable salt thereof, said process comprising the steps of: (i) forming a reaction mixture comprising a compound of formula [II] and a compound of formula [III]; (ii) heating said reaction mixture to a temperature of at least about 130° C.Type: ApplicationFiled: January 21, 2021Publication date: April 6, 2023Inventors: Benjamin SKEAD, Derek LONDESBROUGH, Chris GILL, ALEX HUDSON
-
Patent number: 11578039Abstract: The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, as well as compositions comprising such compounds. These compounds and compositions have uses in the treatment of psychiatric or neurological disorders. Compounds of formula I comprise at least one deuterium atom at the ?-position and consequently have improved oral bioavailability relative to ?-diprotic analogues.Type: GrantFiled: May 6, 2022Date of Patent: February 14, 2023Assignee: Small Pharma Ltd.Inventors: Peter Rands, George Knight, Richard Chubb, Derek Londesbrough, Tiffanie Benway, Zelah Joel
-
Publication number: 20220289755Abstract: In one aspect, the invention relates to a process for preparing a compound of formula (XII), wherein PG is a protecting group, or a compound of formula (XI), comprising the steps of: (i) treating a compound of formula XIII, wherein PG is a protecting group, with N-methylpiperazine to form a compound of formula XII, wherein said compound of formula XII is in the form of a mixture of cis and trans isomers; (ii) combining the mixture formed in step (i) with an organic solvent and heating the solvent mixture so formed; (iii) isolating the trans-isomer of the compound of formula XII from the solvent mixture formed in step (ii); and (iv) optionally treating said trans-isomer of the compound of formula XII with an acid to form a compound of formula XI; and isolating said compound of formula XI. Further aspects of the invention relate to processes for preparing pyrimido-diazepinone derivatives using the above process and intermediates.Type: ApplicationFiled: August 14, 2020Publication date: September 15, 2022Inventors: Benjamin SKEAD, Derek LONDESBROUGH, Michal CZYZEWSKI, Chris ATHERTON, Chris GILL, Alex HUDSON
-
Publication number: 20220281818Abstract: The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, as well as compositions comprising such compounds. These compounds and compositions have uses in the treatment of psychiatric or neurological disorders. Compounds of formula I comprise at least one deuterium atom at the ?-position and consequently have improved oral bioavailability relative to ?-diprotic analogues.Type: ApplicationFiled: May 6, 2022Publication date: September 8, 2022Inventors: Peter RANDS, George KNIGHT, Richard CHUBB, Derek LONDESBROUGH, Tiffanie BENWAY, Zelah JOEL
-
Publication number: 20210395201Abstract: Syntheses of compounds of Formula III from compounds of Formula I via compounds of Formula II are described, as well as particular compounds of Formula III, or pharmaceutically acceptable salts thereof, compositions comprising such compounds, and uses thereof. For example, certain of these compounds and compositions of Formula III have uses in the treatment of psychiatric or neurological disorders.Type: ApplicationFiled: August 26, 2021Publication date: December 23, 2021Applicant: Small Pharma LtdInventors: Peter Rands, George Knight, Richard Chubb, Derek Londesbrough, Tiffanie Benway, Zelah Joel
-
Publication number: 20210070708Abstract: The invention is directed to compounds of general formula (I) and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.Type: ApplicationFiled: July 14, 2020Publication date: March 11, 2021Applicant: BerGenBio ASAInventors: Jason John Shiers, John Paul Watts, Stuart Thomas Onions, Mohammed Abdul Quddus, Joseph William Wrigglesworth, Colin Peter Sambrook-Smith, Alan Naylor, Derek Londesbrough
-
Patent number: 10927113Abstract: The present invention relates to a process for preparing a compound of formula [I], said process comprising the steps of: formula [II]+formula [III]?formula [I] (i) forming a reaction mixture comprising (a) a compound of formula [II], (b) a compound of formula [III] and (c) 1,2-propanediol or polyethylene glycol, or a mixture thereof, and optionally (d) a base; (ii) heating said reaction mixture to a temperature of at least about 150° C.Type: GrantFiled: January 25, 2018Date of Patent: February 23, 2021Assignee: Cyclacel LimitedInventors: Benjamin Mark Skead, Robert Westwood, Derek Londesbrough, Julian Scott Northen, Jonathan Charles Christian Atherton
-
Patent number: 10766861Abstract: The invention is directed to compounds of general formula (I) and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.Type: GrantFiled: May 15, 2019Date of Patent: September 8, 2020Assignee: BerGenBio ASAInventors: Jason John Shiers, John Paul Watts, Stuart Thomas Onions, Mohammed Abdul Quddus, Joseph William Wrigglesworth, Colin Peter Sambrook-Smith, Alan Naylor, Derek Londesbrough
-
Publication number: 20200010421Abstract: The invention is directed to compounds of general formula (I) and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.Type: ApplicationFiled: May 15, 2019Publication date: January 9, 2020Applicant: BerGenBio ASAInventors: Jason John Shiers, John Paul Watts, Stuart Thomas Onions, Mohammed Abdul Quddus, Joseph William Wrigglesworth, Colin Peter Sambrook-Smith, Alan Naylor, Derek Londesbrough
-
Publication number: 20190389863Abstract: The present invention relates to a process for preparing a compound of formula [I], said process comprising the steps of: formula [II]+formula [III]->formula [I] (i) forming a reaction mixture comprising (a) a compound of formula [II], (b) a compound of formula [III] and (c) 1,2-propanediol or polyethylene glycol, or a mixture thereof, and optionally (d) a base; (ii) heating said reaction mixture to a temperature of at least about 150° C.Type: ApplicationFiled: January 25, 2018Publication date: December 26, 2019Inventors: Ben SKEAD, Robert WESTWOOD, Derek LONDESBROUGH, Julian NORTHERN, Chris ATHERTON
-
Patent number: 10336702Abstract: The invention is directed to compounds of general formula (I), and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.Type: GrantFiled: December 23, 2015Date of Patent: July 2, 2019Assignee: BerGenBio ASAInventors: Jason John Shiers, John Paul Watts, Stuart Thomas Onions, Mohammed Abdul Quddus, Joseph William Wrigglesworth, Colin Peter Sambrook-Smith, Alan Naylor, Derek Londesbrough
-
Publication number: 20180029985Abstract: The invention is directed to compounds of general formula (I), and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.Type: ApplicationFiled: December 23, 2015Publication date: February 1, 2018Applicant: BERGENBIO ASInventors: Jason John SHIERS, John Paul WATTS, Stuart Thomas ONIONS, Mohammed Abdul QUDDUS, Joseph William WRIGGLESWORTH, Colin Peter SAMBROOK-SMITH, Alan NAYLOR, Derek LONDESBROUGH